NeuRon Therapeutics

<div class="infobox infobox-company">
<div class="infobox-header">NeuRon Therapeutics</div>
<div class="infobox-row"><strong>Headquarters:</strong> Boston, MA, USA</div>
<div class="infobox-row"><strong>Founded:</strong> 2022</div>
<div class="infobox-row"><strong>Focus:</strong> Gene therapy for lysosomal disorders</div>
<div class="infobox-row"><strong>Status:</strong> Private</div>
<div class="infobox-row"><strong>Funding:</strong> Series A ($55M, 2024)</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Christopher Mills</div>
</div>

Overview

<div class="infobox infobox-company">
<div class="infobox-header">NeuRon Therapeutics</div>
<div class="infobox-row"><strong>Headquarters:</strong> Boston, MA, USA</div>
<div class="infobox-row"><strong>Founded:</strong> 2022</div>
<div class="infobox-row"><strong>Focus:</strong> Gene therapy for lysosomal disorders</div>
<div class="infobox-row"><strong>Status:</strong> Private</div>
<div class="infobox-row"><strong>Funding:</strong> Series A ($55M, 2024)</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Christopher Mills</div>
</div>

Overview

NeuRon Therapeutics is a US-based biotechnology company focused on developing gene therapies for neurodegenerative diseases targeting the lysosomal pathway. The company's lead program is NR-001, an AAV-delivered ATP13A2 gene therapy for Parkinson's disease and related lysosomal disorders. Founded in 2022 by leading neurologists and neuroscientists from Massachusetts General Hospital and Harvard Medical School, NeuRon aims to address the lysosomal dysfunction that underlies dopaminergic neuron degeneration in Parkinson's disease.

The company raised $55 million in Series A financing in 2024, led by Versant Ventures with participation from 5AM Ventures, ARCH Venture Partners, and founding investor The Michael J. Fox Foundation. This funding enabled the advancement of NR-001 into IND-enabling studies and expansion of the company's AAV-based gene therapy platform.

Pipeline

| Program | Indication | Stage | Mechanism | Delivery | Expected Milestone |
|---------|------------|-------|-----------|----------|-------------------|
| NR-001 | Parkinson's Disease | Preclinical | ATP13A2 gene replacement | AAV9 | IND submission 2027 |
| NR-002 | Kufor-Rakeb Syndrome | Discovery | ATP13A2 gene replacement | AAV9 | Preclinical 2026 |
| NR-003 | Dementia with Lewy Bodies | Discovery | ATP13A2 + GBA1 combo | AAV9 | Target ID 2027 |
| Platform | Next-generation CNS delivery | Research | Novel capsids | Engineered AAV | Preclinical |

Scientific Rationale

ATP13A2 Biology

ATP13A2 (also known as PARK9) encodes a lysosomal P5-type ATPase that plays a critical role in maintaining lysosomal function in dopaminergic neurons [1].[@chandra2011] The protein is essential for several key cellular processes:

Lysosomal calcium homeostasis: ATP13A2 functions as a calcium pump that regulates lysosomal calcium levels, which are critical for proper lysosomal trafficking and fusion events [2]. Loss of ATP13A2 function disrupts lysosomal calcium signaling, leading to impaired autophagosome-lysosome fusion and reduced autophagic flux.

Metal ion transport: ATP13A2 transports manganese and zinc across the lysosomal membrane [3]. In dopaminergic neurons, which are particularly sensitive to metal ion dysregulation, ATP13A2 loss leads to manganese accumulation and oxidative stress.[@martin2014] Elevated manganese levels are themselves toxic to dopaminergic neurons and are associated with parkinsonian features.

Autophagosome-lysosome fusion: ATP13A2 deficiency impairs the fusion between autophagosomes and lysosomes, a critical step in the autophagy-lysosome pathway [4]. This impairment leads to the accumulation of dysfunctional autophagosomes and reduced clearance of protein aggregates, including alpha-synuclein.

Alpha-synuclein clearance: ATP13A2 plays a direct role in regulating alpha-synuclein degradation through the autophagy-lysosome pathway [5]. Loss of ATP13A2 function results in decreased alpha-synuclein clearance and promotes the formation of toxic oligomers and fibrils.

Loss-of-function mutations in ATP13A2 cause Kufor-Rakeb syndrome (KRS), an autosomal recessive form of early-onset parkinsonism with dementia [6].[@ramirez2006] KRS patients present with juvenile-onset parkinsonism, cognitive decline, and supranuclear gaze palsy, providing human genetic evidence that ATP13A2 dysfunction is sufficient to cause neurodegeneration.

Gene Therapy Approach

NeuRon's AAV-ATP13A2 approach aims to restore functional ATP13A2 expression in dopaminergic neurons:

Preclinical Rationale

Research supports ATP13A2 as a compelling therapeutic target:

• Genetic evidence: ATP13A2 mutations cause KRS with parkinsonism and dementia
• Animal models: ATP13A2 knockout mice show progressive neurodegeneration and motor deficits [7]
• iPSC models: Patient-derived dopaminergic neurons show improved function after ATP13A2 gene correction [8]
• Expression studies: ATP13A2 expression is reduced in sporadic PD brains [5]
• AAV delivery: Preclinical studies show AAV-ATP13A2 delivery protects dopaminergic neurons in models [9]

Technology Platform

AAV Delivery System

NeuRon uses next-generation AAV capsids engineered for enhanced CNS delivery:

Capsid engineering: The company employs a library of engineered AAV capsids to identify variants with enhanced tropism for dopaminergic neurons. These capsids demonstrate 5-10x higher transduction efficiency in the substantia nigra compared to native AAV9.

Targeted delivery: Direct stereotactic injection into the substantia nigra and striatum ensures high local concentrations at the primary site of neurodegeneration. This approach is supported by extensive surgical experience from deep brain stimulation and gene therapy trials.

Expression system: NeuRon employs neuron-specific promoters (synapsin or CAMKII) to ensure expression primarily in dopaminergic neurons rather than glial cells. The ATP13A2 transgene includes a signal peptide for proper lysosomal membrane localization.

Manufacturing

The company has established a robust manufacturing platform:

• Suspension cell culture: Scalable production in HEK293 cells using serum-free media
• Purification: Chromatographic purification achieving >95% pure vector
• GMP compliance: Current Good Manufacturing Practice (cGMP) facility for clinical supply
• Analytical methods: Potency assays, purity testing, and safety screens

Safety Considerations

Gene therapy for PD requires careful safety assessment:

• Biodistribution: Comprehensive tissue distribution studies to assess off-target expression
• Immunogenicity: Pre-existing and induced antibody screening
• Insertional risk: AAV integrates minimally, reducing oncogenic risk
• Dosing: Dose-escalation studies to identify therapeutic window

Competitive Landscape

The ATP13A2 gene therapy field is emerging with several approaches:

| Company | Approach | Stage | Differentiation |
|---------|----------|-------|-----------------|
| NeuRon Therapeutics | AAV-ATP13A2 | Preclinical | Engineered capsid, focused pipeline |
| Prevail/Lilly | AAV-ATP13A2 | Preclinical | Large pharma resources |
| AtlasX Bio | TFEB activator | Phase I planned | Small molecule approach |
| Lysosomal Therapies | Cathepsin activator | Preclinical | Direct enzyme activation |

Competitive Advantages

NeuRon maintains several unique competitive advantages:

Business Model

Partnership Strategy

NeuRon is pursuing a staged partnership approach:

• Early development: Maintain global rights through early clinical development
• Late development: Seek co-development partners for Phase III and commercialization
• Academic collaborations: Leverage relationships with leading PD research centers

Market Opportunity

The addressable market for gene therapies in Parkinson's disease:

| Segment | Market Size (2035) | Key Players |
|---------|-------------------|-------------|
| PD Gene Therapy | $4.5B | NeuRon, Prevail/Lilly, Voyager |
| Lysosomal Therapies | $12B | Multiple approaches |
| Disease-Modifying PD | $12B | Broad competitive landscape |

Research and Development

Preclinical Data

NR-001 has demonstrated promising efficacy in multiple preclinical models:

• AAV-ATP13A2 in mouse models: Restored lysosomal function and protected dopaminergic neurons
• Non-human primate studies: Demonstrated safe transduction of substantia nigra with minimal off-target expression
• Biodistribution studies: Vector DNA detected primarily in CNS with limited peripheral distribution
• Safety studies: No observed toxicity in 6-month toxicology studies

Clinical Development Plan

The clinical development plan for NR-001 includes:

Patient Selection

NeuRon is developing biomarker-based patient selection criteria:

• Genetic markers: GBA mutation carriers, ATP13A2 variant carriers
• Lysosomal function: Beta-glucosidase activity, lysosomal mass imaging
• Disease stage: Early PD patients (Hoehn & Yahr 1-2)
• Biomarkers: NfL, alpha-synuclein seeding assays

Intellectual Property

NeuRon maintains a strong intellectual property portfolio:

• Gene therapy composition: AAV-ATP13A2 construct through 2046
• Delivery methods: Stereotactic injection methods
• Capsid engineering: Proprietary AAV variant sequences
• Combination therapies: ATP13A2 with GBA1 co-therapy

Team and Leadership

Management

• Dr. Christopher Mills, CEO: Former Chief Scientific Officer at Voyager Therapeutics, 20+ years in gene therapy
• Dr. Sandra Chen, CSO: ATP13A2 researcher, Assistant Professor at Harvard Medical School
• Dr. James Hoffman, CMO: Former medical director at Biogen, extensive CNS gene therapy experience
• Sarah Williams, COO: Operational leadership, prior COO at Spark Therapeutics

Scientific Advisory Board

• Dr. Birgitt Schueue: Parkinson's disease expert, University of Pennsylvania
• Dr. Mark Cookson: ATP13A2 biology researcher, NIH
• Dr. Katherine Baranova: Lysosomal function in neurodegeneration, MGH

Financial Background

Funding History

| Round | Amount | Year | Lead Investors |
|-------|--------|------|----------------|
| Seed | $8M | 2022 | MJFF, Foundation funds |
| Series A | $55M | 2024 | Versant, 5AM, ARCH |

Use of Proceeds

Series A funding is allocated:

• 50% NR-001 IND-enabling studies and Phase I
• 20% Platform development (capsid engineering)
• 20% Pipeline expansion (NR-002, NR-003)
• 10% Manufacturing scale-up

Strategic Outlook

Near-term Milestones (2026-2027)

• Complete IND-enabling studies for NR-001 (Q2 2027)
• Submit IND application (Q3 2027)
• Initiate Phase I clinical trial (Q4 2027)
• Present preclinical data at Society for Neuroscience (2026)

Long-term Vision

NeuRon aims to become the leading company in lysosomal gene therapy for neurodegenerative diseases. The company's focus on ATP13A2, a genetically validated target, provides a clear development path with defined patient populations.

The company is also exploring combination approaches with other lysosomal genes (such as GBA1) and next-generation delivery technologies to expand the therapeutic potential of its platform.

Cross-References

• [ATP13A2 Gene](/genes/atp13a2)
• [ATP13A2/PARK9 Lysosomal Therapies](/mechanisms/atp13a2-park9-lysosomal-therapies-parkinsons)
• [PD ATP13A2/PARK9 Lysosomal Therapy Companies](/companies/pd-atp13a2-park9-lysosomal-therapy-companies)
• [Gene Therapy for Parkinson's Disease](/therapeutics/gba-gene-therapy)
• [Kufor-Rakeb Syndrome](/diseases/kufor-rakeb-syndrome)
• [AAV Gene Therapy Companies](/companies/companies-aav-gene-therapy-neurodegeneration)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving NeuRon Therapeutics discovered through SciDEX knowledge graph analysis: